Lincluden Management Ltd Exits Position in Baxalta Inc (BXLT)

Baxalta Inc (BXLT) : Lincluden Management Ltd has sold out all of its stake in Baxalta Inc during the most recent quarter, according to the disclosure filed by the company on Apr 21, 2016 with the SEC. The investment management company has sold out 176,385 shares of Baxalta Inc which is valued at $7,298,811.

Baxalta Inc closed down -0.42 points or -1.02% at $40.8 with 41,40,444 shares getting traded on Wednesday. Post opening the session at $41.03, the shares hit an intraday low of $40.69 and an intraday high of $41.25 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Interactive Financial Advisors sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 16 shares of BXLT which is valued $662.Clean Yield Group reduced its stake in BXLT by selling 7,780 shares or 19.37% in the most recent quarter. The Hedge Fund company now holds 32,387 shares of BXLT which is valued at $1,311,997. Baxalta Inc makes up approx 0.58% of Clean Yield Group’s portfolio. Donald L. Hagan added BXLT to its portfolio by purchasing 2,000 company shares during the most recent quarter which is valued at $81,020. Baxalta Inc makes up approx 0.07% of Donald L. Hagan’s portfolio.1st Global Advisors boosted its stake in BXLT in the latest quarter, The investment management firm added 1,562 additional shares and now holds a total of 17,629 shares of Baxalta Inc which is valued at $714,151. Baxalta Inc makes up approx 0.10% of 1st Global Advisors’s portfolio. Franklin Street Advisors Inc Nc sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 43,892 shares of BXLT which is valued $1,778,065.

On the company’s financial health, Baxalta Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Feb 16, 2016. Analyst had a consensus of $0.55. The company had revenue of $1763.00 million for the quarter, compared to analysts expectations of $1712.08 million. The company’s revenue was up 4.8% compared to the same quarter last year.

Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.

Leave a Reply

Baxalta Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxalta Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.